# China NMPA Drug Inspection - Sichuan Renhe Traditional Chinese Medicine Pieces Co., Ltd. - Bupleurum (Northern Bupleurum)

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/sichuan-renhe-traditional-chinese-medicine-pieces-co-ltd/ec51eaed-4476-4dbc-b8a8-8536961390d9/
Source feed: China

> China NMPA drug inspection for Sichuan Renhe Traditional Chinese Medicine Pieces Co., Ltd. published June 10, 2021. Drug: Bupleurum (Northern Bupleurum). On June 8, 2021, China’s National Medical Products Administration (NMPA) issued an announcement identifying sixteen batc

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 36 of 2021 from the National Medical Products Administration regarding 16 batches of drugs that did not meet the requirements.
- Company Name: Sichuan Renhe Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2021-06-10
- Drug Name: Bupleurum (Northern Bupleurum)
- Inspection Finding: Impurities do not meet the requirements
- Action Taken: Risk control measures such as suspending sales and use and recalling products will be taken; investigations will be conducted into the reasons for non-compliance and rectification will be carried out; and cases will be filed to investigate illegal activities.
- Summary: On June 8, 2021, China’s National Medical Products Administration (NMPA) issued an announcement identifying sixteen batches of pharmaceutical products that failed to meet quality standards. The inspection involved fourteen manufacturing entities, including Hebei Jiuzheng Pharmaceutical Co., Ltd., Shandong Boshan Pharmaceutical Co., Ltd., and several producers of traditional Chinese medicine such as Anhui Jiancheng and Chongqing Zhongmiao. The testing, conducted by various provincial drug control institutes, revealed significant quality deviations. Major issues included microbial contamination in topical creams and capsules, which poses safety risks, and incorrect fill volumes or weights that could lead to insufficient dosing for patients. Other violations involved excessive moisture content, inaccurate levels of active ingredients, and failures in basic identification and physical appearance standards. In certain traditional Chinese medicine samples, inspectors also discovered unacceptable levels of impurities. These findings were assessed against the standards set by the Pharmacopoeia of the People's Republic of China. Following the Drug Administration Law, the NMPA ordered immediate regulatory actions. The implicated companies must suspend the sale and use of these products and initiate comprehensive recalls. Additionally, the manufacturers are required to investigate the root causes of these failures and implement corrective measures. Local authorities will conduct further legal investigations into the production of substandard drugs and will publicly report the results to ensure transparency and public safety.

Company: https://www.globalkeysolutions.net/companies/sichuan-renhe-traditional-chinese-medicine-pieces-co-ltd/e51f4afc-70ae-41d0-bc7b-96f39d76f879/